ArticleJournal of Taibah University Medical Sciences2025
Outcomes of empagliflozin in nondiabetic fatty liver patients: A randomized controlled trial.
Article in Journal of Taibah University Medical Sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05694923 (Effect of Sodium Glucose Cotransporter Inhibitors on Fatty Liver Disease Patients), which is not on this map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Sodium Glucose Cotransporter Inhibitors on Fatty Liver Disease Patients
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy of Empagliflozin on Liver Enzymes, Lipid Profile and BMI in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review and Meta-Analysis.Endocrinology, diabetes & metabolism · 2026Pooled it
- Comparative Efficacy of SGLT2 Inhibitors in MASLD: Bayesian Network Meta-Analysis of CAP-LSM Outcomes and Time Effects.JGH open : an open access journal of gastroenterology and hepatology · 2026Review
- Empagliflozin in the Absence of Diabetes: A Systematic Review of Its Anthropometric and Metabolic Effects in Humans and Animals.International journal of endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Metabolic fatty liver disease is a common disease with numerous health risks. Life modification remains the primary treatment. Previous studies have shown that the sodium‒glucose cotransporter has a positive effect on improving fatty liver in individuals with diabetes mellitus, but it has not been extensively studied in nondiabetic patients with fatty liver. The aim of this study was to assess the immediate effects of empagliflozin in treating nondiabetic metabolic fatty liver disease. Methods: We conducted a prospective parallel-group open-label study on fifty-five nondiabetic metabolic fatty liver patients. Patients were randomly assigned to two groups: twenty-two patients received lifestyle advice alone (L-arm), and thirty-three patients received lifestyle advice plus empagliflozin 10 mg daily (LE-arm). After 6 months, non-invasive elastography (fibro-scan) was used to check for changes in hepatic steatosis and fibrosis. Body mass index, waist circumference, arterial blood pressure, glycated haemoglobin, and lipid profiles were also used to measure metabolic outcomes. Results: The LE-arm showed a mean CAP reduction of 38 dB/m compared to 8 dB/m in the L-arm (p = 0.001). Moreover, there was a slight improvement in liver fibrosis, as well as improvements in metabolic measures such as blood pressure (p value 0.034), waist circumference (p value 0.01), and weight reduction (2.5 kg vs. 1 kg, p value 0.022). Conclusion: Along with lifestyle changes, empagliflozin may improve hepatic steatosis and the metabolic profile in nondiabetic fatty liver patients. However, conducting a longer term risk‒benefit analysis requires more research. Clinical trial registration: NCT05694923 at 2023-01-19.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.